Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
X-linked retinitis pigmentosa (XLRP), which commonly results from mutations in the RPGR gene or the RP2 gene, is frequently more severe than other forms of retinitis pigmentosa. The onset of legal blindness occurs decades earlier in male patients than in those with other forms of RP; in addition, female XLRP carriers can also be severely affected. In this program, a multispecialty panel provides expert insights into the diagnosis of XLRP, team-based management, and developments in investigational gene therapies for XLRP.
This educational activity is an archive of the live virtual symposium held on July 31, 2025.
Target Audience
This educational curriculum is directed toward retina specialists, ophthalmologists, low vision specialists, optometrists, pediatric ophthalmologists, genetic counselors, and other health care professionals who treat patients with inherited retinal diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate clinical and genetic findings to establish a diagnosis of XLRP
- Outline the roles for eye care professionals and clinical geneticists/genetic counselors in the management of patients with XLRP
- Develop multidisciplinary management plans for patients with XLRP based on clinical presentation and goals of therapy
Ramiro Maldonado, MD
Director, Inherited Retinal Diseases Fellowship
Co-Director, Pediatric Retina
Co-Director, Duke Center for Ophthalmic Genetics
Associate Professor of Ophthalmology
Duke Eye Center
Duke University
Durham, NC
Disclosures: Consultant: Alkeus Therapeutics, Piximune Therapeutics, ProQR Therapeutics, PYC Therapeutics
Rebecca Nelson, MS, CGC
IRD Service Coordinator
Certified Genetic Counselor
Colorado Retina Associates, PLLC
Denver, CO
Disclosures: Consultant: Johnson & Johnson.
Robert A. Sisk, MD, FACS, FASRS
Co-Director, Vitreoretinal Fellowship
Cincinnati Eye Institute
Director, Pediatric Retinal Surgery
Director, Ophthalmic Genetics
Cincinnati Children’s Hospital
Professor of Ophthalmology, Affiliated
University of Cincinnati
Cincinnati, OH
Disclosures: Consultant: Ascidian Therapeutics, Beacon Therapeutics, BlueRock Therapeutics, Carl Zeiss Meditec, EyePoint, Leica Microsystems, Neuracle, Regenxbio, Tern Therapeutics; Advisory Board: Apellis, Astellas, RhyGaze.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here